Immunomic Therapeutics' CEO, Dr. William G. Hearl, to Present at 2012 BIO International in June
Immunomic Therapeutics' CEO, Dr. William G. Hearl, to Present at 2012 BIO International in June
FOR IMMEDIATE RELEASE
/EINPresswire.com/ Lancaster, PA, & Rockville, MD May 24, 2012 - Immunomic Therapeutics, Inc., ("ITI") a privately-held biotechnology company with laboratories in Rockville, MD, announced that it has been accepted to present at the Business Forum during the 2012 Bio International Convention. ITI's CEO, Bill Hearl, will present progress in internal development of LAMP-vax™ vaccines as well as opportunities for co-development.
JRC-LAMP-vax vaccine incorporates Immunomic Therapeutics' proprietary LAMP Technology™. LAMP (Lysosomal Associated Membrane Protein) is a normal and important component of the immune system that is present in the lysosome of all mammals. Incorporating LAMP Technology into vaccine design enables direct presentation of the allergen to the immune system, resulting in an effective and dynamic response. The mechanism of LAMP has been documented in two clinical studies in cancer patients.
In Q1 2012, ITI completed a Series A financing round. Funds are being used for a Phase I clinical study of JRC-LAMP-vax™, a plasmid-based DNA vaccine for treatment of patients with allergies to Japanese Red Cedar pollen. Initiation of the Phase I clinical trial is an important milestone for the Company, whose accomplishments to date include receiving the 2010 Frost & Sullivan Award for Technology Innovation in DNA Vaccines and receiving FDA authorization for its first investigational new drug (IND) application in near record time.
ITI is applying LAMP-vax Technology vaccine platform for developing novel vaccines and immunotherapies for allergies, infectious diseases, and cancer, as well as to enhance the immune response to underperforming products in existing vaccine programs. ITI's CEO, Dr. Bill Hearl will be meeting with potential licensing partners for its JRC-LAMP-vax vaccine at the BIO Business Forum (June 18-21) in Boston. He is scheduled to speak on Tuesday, June 19 at 9:45:00 AM in the Celtics Room (104C).
About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Lancaster, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases. For more information about ITI and LAMP Technology please visit www.immunomix.com.
CONTACT: Dr. Bill Hearl, President / CEO Phone: 1-717-327-1919
Immunomix @ gmail.com
x x x
FOR IMMEDIATE RELEASE
/EINPresswire.com/ Lancaster, PA, & Rockville, MD May 24, 2012 - Immunomic Therapeutics, Inc., ("ITI") a privately-held biotechnology company with laboratories in Rockville, MD, announced that it has been accepted to present at the Business Forum during the 2012 Bio International Convention. ITI's CEO, Bill Hearl, will present progress in internal development of LAMP-vax™ vaccines as well as opportunities for co-development.
JRC-LAMP-vax vaccine incorporates Immunomic Therapeutics' proprietary LAMP Technology™. LAMP (Lysosomal Associated Membrane Protein) is a normal and important component of the immune system that is present in the lysosome of all mammals. Incorporating LAMP Technology into vaccine design enables direct presentation of the allergen to the immune system, resulting in an effective and dynamic response. The mechanism of LAMP has been documented in two clinical studies in cancer patients.
In Q1 2012, ITI completed a Series A financing round. Funds are being used for a Phase I clinical study of JRC-LAMP-vax™, a plasmid-based DNA vaccine for treatment of patients with allergies to Japanese Red Cedar pollen. Initiation of the Phase I clinical trial is an important milestone for the Company, whose accomplishments to date include receiving the 2010 Frost & Sullivan Award for Technology Innovation in DNA Vaccines and receiving FDA authorization for its first investigational new drug (IND) application in near record time.
ITI is applying LAMP-vax Technology vaccine platform for developing novel vaccines and immunotherapies for allergies, infectious diseases, and cancer, as well as to enhance the immune response to underperforming products in existing vaccine programs. ITI's CEO, Dr. Bill Hearl will be meeting with potential licensing partners for its JRC-LAMP-vax vaccine at the BIO Business Forum (June 18-21) in Boston. He is scheduled to speak on Tuesday, June 19 at 9:45:00 AM in the Celtics Room (104C).
About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Lancaster, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases. For more information about ITI and LAMP Technology please visit www.immunomix.com.
CONTACT: Dr. Bill Hearl, President / CEO Phone: 1-717-327-1919
Immunomix @ gmail.com
x x x
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.